CN103596939A
|
|
5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions, and their use
|
AU2012200273A1
|
|
Heterocyclic aspartyl protease inhibitors
|
WO2012058176A1
|
|
Novel heteroaryl-carboxamide derivatives as pdk1 inhibitors
|
WO2012058174A1
|
|
Novel thiazole-carboxamide derivatives as pdk1 inhibitors
|
WO2012058127A2
|
|
Novel compounds that are erk inhibitors
|
WO2012054438A1
|
|
Anti-pcsk9
|
WO2012047569A1
|
|
Fused tricyclic inhibitors of mammalian target of rapamycin
|
WO2012040048A2
|
|
Triazolopyrazinones as p2x7 receptor antagonists
|
WO2012036997A1
|
|
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012036974A1
|
|
Novel thiazol-carboximide derivatives as pdk1 inhibitors
|
WO2012027240A1
|
|
Fused tricyclic inhibitors of mammalian target of rapamycin
|
WO2012027236A1
|
|
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012018538A2
|
|
Bioassays for determining pd-1 modulation
|
WO2011137219A1
|
|
Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
|
WO2011119457A1
|
|
Process for synthesizing 6-bromo-3-(1-methyl-1h-pyrazol-4-yl)-5-(3(r)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine
|
WO2011103441A1
|
|
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
EP2525781A1
|
|
Novel cationic lipids for oligonucleotide delivery
|
WO2011079004A1
|
|
Cell line 3m
|
WO2011075391A1
|
|
Formulations of acadesine
|
CA2782024A1
|
|
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|